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Abstract 
Objective: To assess the consistency between current recommendations that women of 
body weight (BW) or body mass index (BMI) above a defined threshold should use a 
double dose of levonorgestrel (LNG) for emergency contraception (EC) and observed 
frequency of pregnancy in historic studies of single-dose LNG for EC. 
 
Methods: We applied double dose recommendation criteria to individual participant 
level data from three historic studies of the WHO’s Human Reproductive Program to 
categorize subjects into single dose recommended (SDR) and double dose 
recommended (DDR) groups and compared the latter to the former using pregnancy risk 
ratios (RR). 
 
Results: A total of 5859 subjects with 59 pregnancies made up the full dataset. 
Depending on the recommendation source (USA or UK) and inclusion or exclusion of 
heavy outlier data, DDR criteria were satisfied by 3.7 to 18.9% of subjects. Pregnancy 
proportions were mostly lower in DDR than in SDR subjects, with risk ratio estimates 
ranging from zero to 1.17, exceeding unity only when the USA criterion was used with 
outliers included. DDR subjects had a significantly lower relative frequency of pregnancy 
than SDR subjects when the UK criteria were used and outliers excluded (RR = 0.17 
[95%CI: 0.04; 0.70], p = 0.0024). 
 
Conclusions: Our findings are consistent with the notion that there is no real loss of 
pregnancy control with single-dose LNG-EC in high-BMI and/or high-BW users, and 
today’s double dose recommendations were prematurely issued and remain 
questionable. 
 
Keywords: levonorgestrel; contraception, postcoital; treatment failure; body weight; 
body mass index 
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Introduction 
Levonorgestrel (LNG), an orally administered synthetic progestogen developed in the 1970s, is 
the active substance of a widely available and established method of emergency contraception 
(EC). Recently, a concern emerged that there might be a loss of efficacy (LoE) of LNG-EC 
associated with high body mass index (BMI) and/or bodyweight (BW). 
 
The first indication came from a meta-analysis by Glasier et al. [1] of two randomized 
controlled trials comparing the efficacy of ulipristal acetate (UPA) with that of LNG in 
participants from the UK, USA and Ireland [2,3]. Taking a pooled group of normal and 
underweight LNG-EC users as reference, the study estimated a non-significant doubling and a 
significant 4.4-fold increase in the odds of pregnancy in overweight and obese women, 
respectively. The findings were supported by a pooled analysis of the same two studies using 
various analytical approaches [4]. 
 
At the request of the Swedish authority, a European Medicines Agency (EMA) review of LNG 
and UPA EC efficacy was initiated in January 2014. In addition to the meta-analysis by Glasier 
et al., the Agency considered a pooled analysis of the LNG arms of three EC studies by the 
World Health Organization (WHO) involving 17 countries in Africa, Asia, Australia, Europe and 
Latin America. Published later by Gemzell-Danielsson et al. [5], the pooled analysis concluded 
that there was no evidence for pregnancy rates varying across BMI or BW. Importantly, this 
analysis identified a special subgroup of Nigerian women who were exceptionally short for 
their weight. When these severe outliers (very small minority of observations with highly 
untypical values) were included, the analysis detected a significant LoE associated with high 
BMI, which disappeared when they were excluded. The EMA concluded that the data available 
did not support the conclusion that the contraceptive effect of EC pills was reduced in women 
with high bodyweight/BMI, and that EC could continue to be used after unprotected 
intercourse or contraceptive failure, as soon as possible, regardless of the woman’s 
bodyweight [6]. 
 
In 2016, Jatlaoui et al. published a systematic review of secondary analyses including the meta- 
and pooled analyses mentioned above [7]. The authors weighed down the strength of 
evidence of Gemzell-Danielsson et al.’s relative to Glasier/Kapp et al.’s assessment (5812 and 
1731 LNG user subjects, respectively) because they misunderstood and misrepresented the 
analytic approach of the former (they criticized how BMI and BW had been split into too many 
categories, when in fact both were continuous variables), and concluded that women with 
obesity face a higher risk of pregnancy after LNG-EC than those who are normal/underweight. 
 
A year later, a pooled analysis by Festin et al. [8] of the three Gemzell-Danielsson studies plus a 
similar 1993 Hong Kong study [9] again showed that a decrease in the contraceptive effect of 
LNG among obese women was technically detectable, and duly pointed out that this was fully 
dependent on the inclusion of the Nigerian outliers. 
 
Other sources of relevant information for judgment on the LoE issue include pharmacokinetics 
(PK) studies on the impact of obesity on PK parameters of EC preparations [10-13] or regularly 
taken oral contraceptives containing LNG [14-16]. Generally, they found reduced systemic 
exposure parameters for total LNG in obese women. In the PK studies conducted by Edelman 
et al. and Natavio et al. (2019), parameter differences across weight categories were, however, 
much smaller for free LNG, the physiologically active fraction. Importantly, the effect of PK 
differences on ovulation suppression (OS) in an EC relation was either not evaluated in these 
studies or not yet reported about (2019 study by Natavio et al.). 
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The fact that they were not designed to determine the impact of BMI on contraceptive efficacy 
is an overarching limitation of all six original trials comprising the Glasier/Kapp and Gemzell-
Danielsson meta-analyses. These studies had poor sample coverage of high BW/BMI 
individuals because they did not specifically recruit participants with any need of such 
coverage in mind. Also, pregnancy was generally a very rare outcome, which impacted 
negatively on the precision of BMI/BW effect estimates. 
 
Even though the body of evidence available is far from conclusive, the findings above 
prompted two prominent professional organizations to start recommending a double dose 
when it comes to LNG use for EC in women with high BMI or bodyweight. 
 
One such recommendation was formulated by The Faculty of Sexual and Reproductive 
Healthcare (FSRH; United Kingdom). In their 2017 EC Guideline [17], they propose that in LNG-
EC users, a double dose of the normal 1.5 mg formulation be considered for women weighing 
>70 kg or having a BMI >26 kg/m2. 
 
A similar approach is promoted by the American Society for Emergency Contraception (ASEC) 
and states that a double dose may improve efficacy for women with BMI >30kg/m2 [18]. Both 
these recommendations pertain to cases where LNG is opted for after considering other 
choices including the copper intrauterine device and UPA. 
 
The objective of this work was to assess the consistency between these double dose 
recommendations and observed frequency of pregnancy in historic studies of single-dose LNG 
carried out many years before today’s double dose recommendations first emerged. Our 
working hypothesis was that if LNG users of high BW/BMI had poor pregnancy control because 
they took the single rather than the double dose, this should manifest in the form of elevated 
pregnancy rates relative to their fellow study participants who did not meet today’s double 
dose criteria. 
 
Materials and methods 
We had access to individual participant level data from three historic studies of the WHO’s 
Human Reproductive Program [19-21]. Details of these studies as well as data handling, 
filtering, and outlier identification criteria are provided in our earlier publication based on the 
same dataset [5]. In short, all subjects in the LNG arms of these studies used a total dose of 1.5 
mg (equivalent in quantity to the standard single dose). Observations with treatment delay 
missing, negative, or exceeding 72 hours were deleted as LNG-EC is recommended to be taken 
within 72 h from unprotected intercourse. Descriptions and analyses were based on the per-
protocol set and were carried out first including, then excluding an outlier subgroup of 60 
Nigerian subjects who were exceptionally short (<145 cm) for their weight (1 underweight, 3 
normal weight, 15 overweight, 41 obese), found almost exclusively at 3 of 9 study sites in that 
country. These are the same subjects identified in the Gemzell-Danielsson and mentioned in 
the Festin analyses as driving regression estimates towards a false association between high 
BMI/BW and pregnancy. They represent 1% of the sample but 6.8% (4 of 59) of pregnancies, 
with a 6.7% pregnancy rate compared to 0.9% in the rest of the sample. 
 
Subjects were categorized into ‘single dose recommended’ (SDR) and ‘double dose 
recommended’ (DDR) groups, separately by the two sets of double dose recommendation 
criteria (FSRH, ASEC) described above. 
 
Non-pregnant and pregnant subjects’ data were visualized on scatter plots of BMI vs BW, with 
separation according to DDR criteria indicated. DDR and SDR groups were described using 
empirical relative frequencies of pregnancy and compared using pregnancy risk ratios (RR) 
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with 95% confidence intervals (CI). P values less than 0.05 (Fisher’s exact test) were considered 
to indicate a significant difference; 95% CI of RR fully contained within the range 1/1.25 to 1.25 
was considered to indicate equivalence. The statistical package Stata [22] was used for data 
handling and analysis. 
 
Results 
A total of 5859 subjects with 59 pregnancies made up the full dataset. After outlier exclusion, 
the subject count was 5799, with 55 remaining pregnancies. FSRH criteria identified 18.9% 
(18.2% after outlier exclusion) of the sample as potentially benefiting from a double dose, 
while the BMI-based ASEC criterion was satisfied by a much lower 4.4% of all subjects and 
3.7% of non-outliers. 
 
Outliers appeared on the scatter plot as a patch of loosely scattered observations deviating 
from the main body of data – a densely packed, oval-shaped cloud consistent with a linear 
relationship between BMI and BW – towards the higher-BMI range (compare Figures 1, 3 with 
Figures 2, 4). 
 
Pregnancy proportions in study subsamples defined by DDR criteria ranged from 0% to 1.17% 
depending on outlier inclusion, while risk ratio estimates did so from zero to 1.17 (Table 1). 
Even though all subjects were single dosed, proportions were mostly lower in DDR than in SDR 
subjects (RR being below 1), rather than the other way around as expectable if tendencies in 
the data were consistent with the double dose approach. The only exception to this was the 
categorization by the ASEC criterion with outliers included. Due primarily to the sizable width 
of confidence intervals around rate ratio estimates, observed pregnancy rates in SDR and DDR 
subjects were not similar enough to satisfy pre-defined criteria for their equivalence in any of 
the comparative relations. Characterized by a risk ratio of around one-sixth, DDR subjects had 
a significantly lower relative frequency of pregnancy than SDR subjects when the FSRH criteria 
were used and outliers were excluded. No pregnancies were observed in the DDR group after 
the exclusion of outliers in the comparison based on the ASEC criterion. 
 
Discussion 
This evaluation applied currently circulated double dose recommendation criteria to historic 
data of single dose users from three LNG EC studies between 1998 and 2010. 
 
If the single dose was insufficient for adequate pregnancy control in past overweight or obese 
users who otherwise satisfy today’s double dose recommendation criteria, it was expected to 
be revealed by an observable elevated frequency of pregnancy in their subgroup as compared 
to other users. In contrast, our data indicate generally lower pregnancy proportions in DDR 
than in SDR subjects. 
 
Although equivalence was not statistically confirmed due to estimates based on very low 
pregnancy counts producing wide confidence intervals, subjects satisfying the then-
nonexistent double dose criterion and taking a single dose experienced similar or significantly 
better control of pregnancy than those who would continue to be offered a single dose today. 
This high level of pregnancy control seen in DDR subjects might in part be explained by the fact 
that fecundability rates are known to significantly decrease with increasing body weight. 
Unfortunately, it is not possible to establish a baseline (off-EC) pregnancy rate specifically in 
these historic subjects who, by all three source trials’ eligibility criteria, were healthy and with 
regular menstrual cycles, thus do not generally represent the overall female population in any 
weight category. Due to this major limitation, we cannot reliably separate the observed 
sufficient pregnancy control into its key components, i.e. the contraceptive efficacy of a single-
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dose LNG EC pill in DDR subjects and the general limiting effect of increased body weight on 
fecundability. 
 
Of note, the two different DDR definitions offered by the FSRH and ASEC have an about four-
fold difference between them in the percentage of users they identify as potentially benefiting 
from elevated dosage. While this difference might reduce if the European and US 
recommendations were applied to their respective local populations only, it remains doubtful 
whether differences in local distributions of body composition fully explain the apparent 
contrast between the two organizations’ views. 
 
Unfortunately, we are not in the position to conduct a similar consistency evaluation of data 
from the two studies that first generated the LoE signal. These are proprietary studies with no 
Individual Participant Data sharing statements provided for them. Whether the LoE issue has 
real substance to it has long been undecided, and a straightforward, low-cost way of gaining 
more insight would be to carry out an overall pooled analysis of the six historic studies. 
However, doing so would require that the data from all these studies be made accessible to 
the same analyst. 
 
 A different, more resource intensive approach for future clarification efforts would be based 
on targeted research into both the ovarian suppression efficacy and the PK behaviour of LNG 
as a function of BMI and/or BW within the same trial. Through appropriate design and 
targeted recruitment, a mixed pharmacodynamic (PD) and PK study could ensure avoiding the 
shortcomings of historic studies related to poor sample coverage at distribution extremes, lack 
of endpoints with direct clinical importance, and prohibitive rarity of outcome events. 
 
Conclusions 
Our findings are consistent with the notion that there is no real loss of pregnancy control with 
single-dose LNG-EC in high-BMI and/or high-BW users, and today’s double dose 
recommendations were prematurely issued and remain questionable. 
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Table 
DDR criteria by Outliers SDR subjects DDR subjects RR [95% CI] p 
FSRH included 53/4751 = 1.12% 6/1108 = 0.54% 0.49 [0.21; 1.13] 0.0947 
FSRH excluded 53/4746 = 1.12% 2/1053 = 0.19% 0.17 [0.04; 0.70] 0.0024 
ASEC included 56/5603 = 1.00% 3/256 = 1.17% 1.17 [0.37; 3.72] 0.7432 
ASEC excluded 55/5584 = 0.98% 0/215 = 0.00% 0.00 [    N/A   ] 0.2697 
Table 1. Pregnancy proportions (%) and risk ratios (RR) for SDR (single dose 
recommended) and DDR (double dose recommended) subjects in subsamples defined 
by DDR criteria and outlier inclusion 
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Figure 3 
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Figure captions 
Figure 1. Body mass index (BMI) versus bodyweight (BW) in non-pregnant and 
pregnant SDR and DDR subjects. Dashed lines indicate FSRH double dose 
recommendation cut points on the BMI and BW scales. SDR, single dose 
recommended; DDR, double dose recommended 
Figure 2. Body mass index (BMI) versus bodyweight (BW) in non-pregnant and 
pregnant SDR and DDR subjects with outlier observations excluded. Dashed lines 
indicate FSRH double dose recommendation cut points on the BMI and BW scales. 
SDR, single dose recommended; DDR, double dose recommended 
Figure 3. Body mass index (BMI) versus bodyweight (BW) in non-pregnant and 
pregnant SDR and DDR subjects. Dashed line indicates ASEC double dose 
recommendation cut point on the BMI scale. SDR, single dose recommended; DDR, 
double dose recommended 
Figure 4. Body mass index (BMI) versus bodyweight (BW) in non-pregnant and 
pregnant SDR and DDR subjects with outlier observations excluded. Dashed line 
indicates ASEC double dose recommendation cut point on the BMI scale. SDR, single 
dose recommended; DDR, double dose recommended 
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